EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study

Beobachtungsstudie zur Wirksamkeit und Sicherheit von Nivolumab plus Chemotherapie bei unbehandeltem fortgeschrittenem oder rezidivierendem Magenkarzinom in japanischen Real-World-Daten: die G-KNIGHT-Studie

Shigenori Kadowaki, Tomoyuki Otsuka, Keiko Minashi, Shinichi Nishina, Hiroshi Yabusaki, Chiaki Inagaki, Tomohiro Nishina, Hisateru Yasui, Hiroshi Matsuoka, Nozomu Machida, Masahiro Tsuda, Fumio Nagashima und 8 weitere

Gastric Cancer · 2025-09 · 28 (5) · 955-967

DOI: 10.1007/s10120-025-01641-7 ↗

Auf einen Blick

Bei 527 japanischen Patient:innen war Nivolumab plus Chemotherapie mit einer ORR von 65,6 % und einer medianen rwPFS von 6,9 Monaten verbunden. TRAEs traten bei 91,3 % auf, 40,4 % waren Grad ≥ 3.

Fragestellung

Wie wirksam und sicher ist Nivolumab plus Chemotherapie als First-Line-Therapie bei unbehandeltem fortgeschrittenem oder rezidivierendem Magenkarzinom in Japan?

Methode

Beobachtungsstudie an 23 japanischen Zentren; Einschluss von Patient:innen von November 2021 bis Juni 2023; Auswertung von ORR, rwPFS und TRAEs sowie Subgruppen nach Alter und PD-L1 CPS.

Ergebnisse

527 Patient:innen, medianes Follow-up 10,4 Monate. ORR 65,6 % (95 %-KI 59,9–70,9). Medianes rwPFS 6,9 Monate (95 %-KI 6,2–7,6). TRAEs bei 91,3 %, Grad ≥ 3 bei 40,4 %.

Schlussfolgerung der Autor:innen

Die Autor:innen schließen, dass die große Real-World-Studie die Wirksamkeit und Sicherheit von Nivolumab plus Chemotherapie bei unbehandeltem japanischem Magenkarzinom unterstützt.

Kernaussagen

  • ORR: 65,6 % (95 %-KI 59,9–70,9)
  • Medianes rwPFS: 6,9 Monate
  • TRAEs bei 91,3 %, Grad ≥ 3 bei 40,4 %

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Gastric Cancer, online erschienen am 09.07.2025. Verfasst von Shigenori Kadowaki und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan. skadowaki@aichi-cc.jp. Hauptthemen laut MEDLINE: Nivolumab, Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb, Ono Pharmaceutical.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nivolumab plus chemotherapy has shown efficacy in clinical trials for advanced or recurrent gastric cancer (GC). However, real-world utilization data are limited. In this study, we aimed to assess the effectiveness, safety, and treatment status of first line nivolumab plus chemotherapy in Japanese patients with treatment-naïve advanced or recurrent GC.

Methods

Untreated patients with advanced or recurrent GC who initiated nivolumab plus chemotherapy as first line treatment from November 2021 to June 2023 across 23 Japanese sites were enrolled in this observational study (G-KNIGHT). This report focused on the objective response rate (ORR), real-world progression-free survival (rwPFS), and the treatment-related adverse event (TRAE) incidence. Furthermore, subgroup analyses for ORR and rwPFS were conducted for patients stratified by various factors including age and the programmed cell death ligand 1 (PD-L1) combined positive score (CPS).

Results

Among 527 patients (median age, 70.3 years; 25.2% aged ≥ 75 years; 65.5% male; 84.3% with advanced GC), the median follow-up period was 10.4 (interquartile range, 6.7–15.2) months. The ORR was 65.6% (95% confidence interval [CI], 59.9–70.9%). The median rwPFS (months, 95% CI) was 6.9 (6.2–7.6); by subgroups: age < 75 years, 6.7 (6.0–7.5); age ≥ 75 years, 7.4 (6.2–8.6); PD-L1 CPS < 1, 7.5 (6.5–9.0); CPS 1–5, 6.2 (5.5–8.0); and CPS ≥ 5, 7.0 (6.2–8.2). TRAEs occurred in 91.3% of patients, with 40.4% experiencing grade ≥ 3 events.

Conclusions

This large-scale real-world study supports the effectiveness and safety of nivolumab plus chemotherapy in untreated Japanese patients with advanced or recurrent GC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalHumansMaleFemaleAgedMiddle AgedJapanAged, 80 and overAdultProgression-Free SurvivalSurvival RateEast Asian People

Stichwörter der Autor:innen

JapanNivolumabObservational studyStomach neoplasms

Substanzen

Nivolumab

Autor:innen und Institutionen

  • Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan. skadowaki@aichi-cc.jp.
  • Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Clinical Trial Promotion Department, Chiba Cancer Center, Chiba, Japan.
  • Department of Medical Oncology, Kurashiki Central Hospital, Okayama, Japan.
  • Department of Gastroenterological Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
  • Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan.

Förderung

  • Bristol Myers Squibb
  • Ono Pharmaceutical

Zitieren

APA

Kadowaki, S., Otsuka, T., Minashi, K., Nishina, S., Yabusaki, H., Inagaki, C., Nishina, T., Yasui, H., Matsuoka, H., Machida, N., Tsuda, M., Nagashima, F., Hosaka, H., Matsubara, J., Arai, H., Ida, S., Kimijima, Y., Matsuda, Y., Muto, M., & Muro, K. (2025). An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study. Gastric Cancer, 28(5), 955-967. https://doi.org/10.1007/s10120-025-01641-7

Vancouver

Kadowaki S, Otsuka T, Minashi K, Nishina S, Yabusaki H, Inagaki C, et al. An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study. Gastric Cancer. 2025;28(5):955-967. doi:10.1007/s10120-025-01641-7

BibTeX
@article{Kadowaki2025,
  author = {Kadowaki, Shigenori and Otsuka, Tomoyuki and Minashi, Keiko and Nishina, Shinichi and Yabusaki, Hiroshi and Inagaki, Chiaki and Nishina, Tomohiro and Yasui, Hisateru and Matsuoka, Hiroshi and Machida, Nozomu and Tsuda, Masahiro and Nagashima, Fumio and Hosaka, Hisashi and Matsubara, Junichi and Arai, Hiroyuki and Ida, Satoshi and Kimijima, Yuya and Matsuda, Yuko and Muto, Manabu and Muro, Kei},
  title = {An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study},
  journal = {Gastric Cancer},
  year = {2025},
  volume = {28},
  number = {5},
  pages = {955--967},
  doi = {10.1007/s10120-025-01641-7}
}
Kostenlos starten →